Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Interest & Investment Income (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Interest & Investment Income for 3 consecutive years, with $3.9 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 24.49% to $3.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.5 million through Dec 2025, down 35.69% year-over-year, with the annual reading at $16.5 million for FY2025, 35.69% down from the prior year.
  • Interest & Investment Income hit $3.9 million in Q4 2025 for Immunocore Holdings, down from $4.1 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $8.2 million in Q1 2024 to a low of $3.1 million in Q1 2023.
  • Historically, Interest & Investment Income has averaged $5.0 million across 3 years, with a median of $4.7 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: soared 163.62% in 2024 and later plummeted 49.36% in 2025.
  • Year by year, Interest & Investment Income stood at $5.4 million in 2023, then dropped by 4.91% to $5.2 million in 2024, then dropped by 24.49% to $3.9 million in 2025.
  • Business Quant data shows Interest & Investment Income for IMCR at $3.9 million in Q4 2025, $4.1 million in Q3 2025, and $4.3 million in Q2 2025.